216
Participants
Start Date
September 30, 2011
Primary Completion Date
December 31, 2015
Study Completion Date
June 30, 2017
Pravastatin
"Treatment:~Patients will be randomized in two groups, A and B:~* Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~* Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h."
Hospital Donostia, Instituto Biodonostia, Donostia / San Sebastian
INSTITUTO BIODONOSTIA
UNKNOWN
Hospital Donostia
OTHER